These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 18342647

  • 1. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
    Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P.
    J Drugs Dermatol; 2009 Sep; 8(9):837-44. PubMed ID: 19746676
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P.
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [Abstract] [Full Text] [Related]

  • 4. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB, Reyes-Habito CM, Lima XT, Kimball AB.
    J Drugs Dermatol; 2013 Jun 01; 12(6):633-7. PubMed ID: 23839178
    [Abstract] [Full Text] [Related]

  • 5. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW, Koltun W, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Cutis; 2008 Aug 01; 82(2):143-50. PubMed ID: 18792547
    [Abstract] [Full Text] [Related]

  • 6. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
    Koltun W, Maloney JM, Marr J, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr 01; 155(2):171-5. PubMed ID: 21288628
    [Abstract] [Full Text] [Related]

  • 7. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH, Gollnick H, Schellschmidt I.
    Cutis; 2004 Aug 01; 74(2):123-30. PubMed ID: 15379365
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T.
    Contraception; 2009 Apr 01; 79(4):282-9. PubMed ID: 19272497
    [Abstract] [Full Text] [Related]

  • 9. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
    Klipping C, Duijkers I, Trummer D, Marr J.
    Contraception; 2008 Jul 01; 78(1):16-25. PubMed ID: 18555813
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
    Hernádi L, Marr J, Trummer D, De Leo V, Petraglia F.
    Contraception; 2009 Jul 01; 80(1):18-24. PubMed ID: 19501211
    [Abstract] [Full Text] [Related]

  • 11. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L, Kunz M, Marr J.
    Contraception; 2009 Nov 01; 80(5):445-51. PubMed ID: 19835718
    [Abstract] [Full Text] [Related]

  • 12. YAZ and the novel progestin drospirenone.
    Mishell DR.
    J Reprod Med; 2008 Sep 01; 53(9 Suppl):721-8. PubMed ID: 18980044
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A.
    Contraception; 2010 Jun 01; 81(6):501-9. PubMed ID: 20472117
    [Abstract] [Full Text] [Related]

  • 14. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Gerlinger C, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2012 May 01; 162(1):91-5. PubMed ID: 22391750
    [Abstract] [Full Text] [Related]

  • 15. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr 01; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G, Cunliffe WJ, Binder N, Höschen K.
    Contraception; 2009 Jul 01; 80(1):25-33. PubMed ID: 19501212
    [Abstract] [Full Text] [Related]

  • 17. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S, Marr J, Diefenbach K, Trummer D, Sampson-Landers C.
    Contraception; 2012 Jan 01; 85(1):42-50. PubMed ID: 22067790
    [Abstract] [Full Text] [Related]

  • 18. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA.
    Contraception; 2005 Dec 01; 72(6):414-21. PubMed ID: 16307962
    [Abstract] [Full Text] [Related]

  • 19. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H, Schürmann R, Benda N.
    Contraception; 2008 Mar 01; 77(3):171-6. PubMed ID: 18279686
    [Abstract] [Full Text] [Related]

  • 20. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, Coelingh Bennink HJ.
    Contraception; 2015 Feb 01; 91(2):134-42. PubMed ID: 25496917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.